Last reviewed · How we verify
Percutaneous sirolimus
Percutaneous sirolimus is a mTOR inhibitor Small molecule drug developed by Children's Hospital of Fudan University. It is currently FDA-approved for Percutaneous delivery for localized skin conditions (specific indication not definitively established in public literature). Also known as: Rapamycin.
Percutaneous sirolimus is a topical formulation of the immunosuppressant sirolimus delivered through the skin to inhibit mTOR signaling and suppress immune cell proliferation.
Percutaneous sirolimus is a topical formulation of the immunosuppressant sirolimus delivered through the skin to inhibit mTOR signaling and suppress immune cell proliferation. Used for Percutaneous delivery for localized skin conditions (specific indication not definitively established in public literature).
At a glance
| Generic name | Percutaneous sirolimus |
|---|---|
| Also known as | Rapamycin |
| Sponsor | Children's Hospital of Fudan University |
| Drug class | mTOR inhibitor |
| Target | mTOR (mechanistic target of rapamycin) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Sirolimus (rapamycin) is an mTOR inhibitor that blocks T-cell and B-cell proliferation by preventing progression through the cell cycle. When delivered percutaneously, it achieves local immunosuppressive effects at the site of application while minimizing systemic exposure. This mechanism makes it suitable for localized inflammatory or proliferative skin conditions.
Approved indications
- Percutaneous delivery for localized skin conditions (specific indication not definitively established in public literature)
Common side effects
- Local skin irritation
- Erythema
- Pruritus
Key clinical trials
- MIRAGE Study: Clinical Outcomes of the Mamba Sirolimus-Eluting PTCA Balloon (PHASE4)
- Ultrathin Strut Sirolimus-eluting Stent With Bioabsorbable Polymer in Patients Receiving Chronic Oral Anticoagulation
- EVERO Drug-coated Balloon (DCB) Randomized Trial (NA)
- Multivessel TALENT (NA)
- Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma (NA)
- Prospective Registry of ihtDEStiny® Coronary Stent in Regular PCI Practice
- Bioresorbable Sirolimus-eluting scaffold in de Novo Coronary Artery Lesions (NA)
- Bioresorbable Sirolimus-Eluting Scaffold Treatment for Below the Knee Disease (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Percutaneous sirolimus CI brief — competitive landscape report
- Percutaneous sirolimus updates RSS · CI watch RSS
- Children's Hospital of Fudan University portfolio CI
Frequently asked questions about Percutaneous sirolimus
What is Percutaneous sirolimus?
How does Percutaneous sirolimus work?
What is Percutaneous sirolimus used for?
Who makes Percutaneous sirolimus?
Is Percutaneous sirolimus also known as anything else?
What drug class is Percutaneous sirolimus in?
What development phase is Percutaneous sirolimus in?
What are the side effects of Percutaneous sirolimus?
What does Percutaneous sirolimus target?
Related
- Drug class: All mTOR inhibitor drugs
- Target: All drugs targeting mTOR (mechanistic target of rapamycin)
- Manufacturer: Children's Hospital of Fudan University — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Percutaneous delivery for localized skin conditions (specific indication not definitively established in public literature)
- Also known as: Rapamycin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing